phase
clinic
trial
approv
may
us
food
drug
administr
evalu
rna
interfer
rnai
nucleic
acid
therapi
infect
trial
first
employ
lentiviru
vector
transduct
hematopoiet
stem
cell
hsc
later
differenti
differ
immun
cell
vector
design
first
test
target
genet
combin
three
site
hiv
replic
also
first
employ
rnai
therapeut
design
use
short
hairpin
rna
shrna
direct
tatrev
site
hiv
genom
two
nucleic
acid
construct
place
vector
includ
ribozym
design
decreas
host
cell
express
degrad
mrna
oligonucleotid
decoy
bind
sequest
tar
protein
synthes
hivinfect
cell
gene
therapi
previous
focus
correct
dna
defect
stop
death
occur
two
differ
human
trial
strategi
gene
therapi
sinc
direct
inhibit
effect
aberr
noncellular
gene
hiv
trial
employ
mechan
associ
express
ribozym
antisens
rna
neither
approach
success
anticip
target
therapi
recognit
rnai
natur
biolog
mean
silenc
specif
gene
led
widespread
use
laboratori
tool
examin
gene
function
antivir
potenti
rnai
quickli
realiz
test
rnai
pathway
intracellular
mechan
involv
regul
gene
express
rnai
provid
cellular
protect
invas
nucleic
acid
viral
genom
effect
abnorm
gene
rnai
first
observ
plant
found
conserv
oper
eukaryot
includ
human
although
short
interf
rna
sirna
use
extens
vitro
success
manipul
rnai
process
vivo
potenti
antivir
use
occur
subsequ
report
suggest
adequ
feasibl
plan
phase
clinic
trial
sever
review
focus
differ
aspect
use
rnai
viral
infect
clinic
applic
provid
detail
descript
figur
mechan
involv
rnai
cellular
pathway
rnai
make
use
doublestrand
rna
dsrna
speci
found
transient
cell
event
associ
rnai
occur
cytoplasm
interfer
mechan
employ
dsrna
sirna
form
microrna
mirna
usual
around
basepair
bp
bp
length
size
limit
impos
small
rna
speci
help
avoid
initi
immun
respons
especi
interferon
ifn
aris
respons
presenc
dsrna
longer
bp
length
contribut
pathogen
process
virus
rnai
short
rna
associ
complex
hostcel
enzym
includ
rnainduc
silenc
complex
risc
argonaut
initi
degrad
target
rna
synthes
cell
sirna
dsrna
perfectli
match
sequenc
mirna
imperfectli
match
dsrna
basic
sirna
mirna
gener
endogen
cleavag
longer
precursor
cellular
dsrna
cellular
enzym
dicer
rnase
iii
fig
synthet
sirna
may
also
includ
hairpin
structur
shrna
may
function
like
sirna
cleavag
dicer
altern
sirna
alreadi
work
length
introduc
cell
bypass
cleavag
act
intracellular
copi
mrna
infecti
agent
virus
aggreg
protein
enzym
compris
risc
attach
either
sirna
mirna
thought
one
enzymat
function
contain
risc
cleav
one
strand
sirna
mirna
usual
sens
strand
activ
risc
process
activ
complex
find
bind
target
messeng
rna
mrna
contain
complementari
nucleotid
sequenc
match
strand
remain
risc
bind
interfer
express
target
mrna
bind
perfect
would
seen
sirna
target
mrna
cleav
one
enzym
risc
releas
activ
risc
use
bind
exact
similar
seen
mirna
activ
complex
disrupt
mrna
express
block
translat
rnai
natur
mean
cellular
gene
regul
adapt
use
defens
mechan
sever
characterist
rnai
pathway
particularli
attract
develop
therapi
infecti
agent
virus
mechan
provid
way
act
target
specif
viral
replic
cycl
reach
easili
current
medicin
therapeut
approach
involv
natur
host
cell
compon
would
potenti
reduc
toxic
host
cell
occur
treatment
convent
drug
rnai
treatment
would
design
knowledg
target
viral
sequenc
possibl
gener
test
prospect
sirna
quickli
interfer
would
requir
target
function
area
viral
protein
would
allow
target
anywher
viral
mrna
design
strategi
could
proceed
soon
sequenc
data
target
genom
obtain
even
activ
encod
target
region
genom
known
featur
clearli
allow
increas
flexibl
design
number
target
avail
rnai
agent
releas
activ
risc
allow
recycl
repeat
use
due
stabil
efficaci
enzym
risc
presenc
sirna
introduc
exogen
short
live
reduc
possibl
toxic
treatment
despit
promis
treatment
rnai
challeng
involv
design
rnai
therapi
work
vivo
includ
deliveri
product
specif
target
cell
efficaci
amount
decreas
potenti
unintent
bind
sirna
mirna
highli
homolog
offtarget
sequenc
cell
genom
may
alter
cell
function
detriment
develop
escap
mutat
target
sequenc
especi
target
viral
genom
concern
identifi
possibl
problem
associ
shortterm
administr
sirna
issu
yet
unidentifi
may
associ
longer
administr
rnai
therapi
studi
demonstr
potenti
rnai
therapi
strongli
perform
vivo
use
rnai
interven
effect
acut
infect
pathogenesi
particularli
solid
data
report
herp
simplex
viru
type
respiratori
syncyti
viru
rsv
infect
mice
acquir
virus
transmiss
rout
human
mice
inocul
intravagin
viru
develop
infect
appar
diseas
sometim
paralyt
lethal
candid
sirna
target
dna
bind
protein
administ
vagin
lipid
mixtur
use
normal
vitro
transfect
previou
evalu
deliveri
agent
show
efficaci
without
elicit
inflammatori
respons
ifn
product
mice
treat
sirna
hour
challeng
hour
challeng
two
ld
die
compar
control
group
n
also
surviv
clear
infect
day
suggest
sirna
treatment
may
decreas
hsv
pathogen
lessen
prevent
viral
shed
short
period
evid
escap
mutant
sirna
treatment
mice
inocul
intranas
rsv
show
maxim
viru
growth
lung
day
later
increas
respiratori
rate
mucu
secret
inflamm
bronchoconstrict
mice
inocul
parainfluenza
viru
show
similar
effect
mice
inhal
sirna
direct
rsv
p
protein
dilut
transfect
reagent
tissu
cultur
medium
viru
challeng
display
infect
sirna
given
challeng
infect
reduc
faster
cure
rate
rsv
parainfluenza
viru
sometim
identifi
clinic
sampl
concurr
administr
two
differ
sirna
one
viru
also
examin
mice
pretreat
sirna
mixtur
challeng
mixtur
virus
protect
diseas
sign
viral
infect
evid
harvest
lung
tissu
ifn
tissu
also
absent
report
rnai
treatment
respiratori
virus
influenza
sever
acut
respiratori
syndrom
coronaviru
sarscov
evalu
variabl
sirna
deliveri
specif
two
studi
use
influenza
use
differ
strategi
deliv
sirna
target
influenza
gene
encod
nucleoprotein
polymeras
one
studi
sirna
cation
polym
inject
retroorbit
mice
altern
shrna
target
influenza
protein
place
lentiviru
vector
transfect
intratrach
retroorbit
anoth
studi
sirna
dilut
phosphat
buffer
salin
administ
intraven
tail
vein
follow
challeng
influenza
sirna
mixtur
intranas
strategi
appear
work
prophylact
infect
increas
surviv
reduc
lung
viral
titer
decreas
weight
loss
infect
sarscov
studi
perform
rhesu
macaqu
show
diseas
characterist
similar
sever
infect
human
sar
outbreak
two
sirna
test
spike
protein
nonstructur
viral
protein
gene
exact
sequenc
homolog
laboratori
strain
sequenc
global
isol
homolog
human
genom
sequenc
note
sarscov
replic
patholog
occur
insid
lung
effect
carrier
sought
would
reach
lung
tissu
three
group
macaqu
treat
intranas
sirna
glucosewat
carrier
infect
differ
dose
regimen
group
display
symptom
diseas
sirnatr
anim
gener
lower
fever
nearli
normal
temperatur
one
sirna
link
fever
suppress
also
decreas
antivir
igg
level
develop
day
control
milder
diffus
alveolar
damag
lower
viru
replic
fewer
infect
cell
deep
lung
tissu
rnai
intervent
japanes
enceph
viru
west
nile
viru
infect
demonstr
complex
deliveri
sirna
tissu
flavivirus
travel
brain
caus
meningitisenceph
human
infect
mice
show
similar
diseas
viral
envelop
gene
highli
conserv
virus
target
sirna
shrna
lentiviru
vector
optim
differ
lipid
deliveri
agent
dose
intracerebr
singl
dose
sirna
given
hour
four
ld
viru
mice
surviv
mice
receiv
sirna
hour
infect
surviv
indefinit
evid
viru
replic
brain
note
surviv
mice
day
later
histopatholog
viru
cultur
sirna
also
develop
suppress
japanes
enceph
viru
west
nile
viru
infect
vivo
rnai
therapi
chronic
infect
present
differ
challeng
chronic
infect
establish
site
peripher
initi
site
infect
persist
infect
tissu
may
shed
viru
continu
potenti
oncogenesi
virus
caus
chronic
sequela
often
produc
indistinct
mild
acut
diseas
symptom
resolv
quickli
damag
chronic
infect
may
result
longterm
immun
respons
continu
presenc
viral
antigen
pharmaceut
treatment
chronic
infect
reduc
diseas
suppress
viral
replic
rnai
would
act
similarli
use
rnai
suppress
chronic
infect
requir
sirna
shrna
reach
potenti
prolong
express
appropri
target
cell
longterm
express
may
facilit
use
shrna
deliv
vector
rather
sirna
exist
transient
initi
rnai
strategi
chronic
infect
focus
reduc
acut
viral
replic
reduc
develop
pathogenesi
chronic
phase
express
rnai
agent
deliveri
monitor
activ
two
shrnaplasmid
construct
hepat
b
viru
hbv
assess
cotransfect
hbv
genom
mice
shrna
express
liver
show
plasmid
reach
appropri
organ
cell
tail
vein
inject
hbv
infect
suppress
inhibit
evidenc
substanti
decreas
replic
form
hbv
hepat
b
surfac
antigen
number
hepatocy
contain
hbv
antigen
similar
studi
use
shrna
region
conserv
among
hbv
genotyp
yield
similar
result
differ
report
hbv
inocul
sirna
mice
chronic
hbv
infect
observ
long
day
infect
compar
control
sirna
treatment
reduc
viral
load
level
similar
antivir
treatment
lamivudin
adefovir
interferon
knockout
mice
infect
coxsacki
viru
treat
hour
infect
tail
vein
intraperiton
transfect
sirna
site
code
proteinas
protein
protein
cleav
dystrophin
myocardi
cell
potenti
lead
dilat
cardiomyopathi
acut
viral
infect
resolv
histolog
examin
show
heart
cell
express
sirna
transfect
viru
detect
heart
lung
treat
anim
present
control
mice
viru
liver
significantli
reduc
data
suggest
rnai
optim
could
lessen
inflamm
respond
activ
replic
viru
myocardi
cell
decreas
heart
damag
anoth
approach
use
rnai
interven
chronic
infect
suppress
cellular
gene
suscept
cell
need
viru
replic
without
caus
perman
harm
common
target
cellular
receptor
use
viral
entri
vitro
studi
examin
inhibit
adenoviru
infect
reduc
express
common
cellular
receptor
coxsackieadenoviru
receptor
like
adenoviru
establish
persist
infect
heart
cell
receiv
shrnavector
instead
sirna
partli
cell
cardiac
origin
difficult
transfect
infect
cell
cardiac
muscl
cell
line
inhibit
dosedepend
manner
shrna
silenc
coxsackieadenoviru
receptor
less
protect
challeng
adenoviru
downregul
receptor
primari
rat
neonat
cardiomyocyt
occur
around
day
receiv
shrna
challeng
either
viru
less
viru
replic
occur
challeng
earlier
reduc
viral
yield
cellular
gene
encod
protein
interact
noncod
region
hepat
c
viru
hcv
target
protein
found
cell
type
present
cell
hcv
construct
replic
area
hcv
genom
bind
conserv
six
hcv
genotyp
rnai
target
reduc
hcv
protein
express
cell
impli
success
inhibit
protein
reduc
amount
hcv
mrna
synthes
infect
cell
sirna
target
cellular
fa
gene
mice
use
inhibit
induct
fulmin
hepat
fa
mediat
apoptosi
administ
hemodynam
tail
vein
inject
sirna
present
liver
within
hour
prevent
liver
cell
necrosi
inflamm
develop
fibrosi
protect
transient
reduct
fa
protein
mrna
peak
day
return
normal
within
day
fasrel
gene
affect
although
model
address
viral
infect
suggest
suppress
fa
might
reduc
sever
chronic
liver
damag
induc
viral
infect
rnai
reduct
oncogenesi
demonstr
model
human
papillomaviru
hpv
tumor
format
tumor
form
caski
cell
contain
copi
implant
leg
nude
mice
sirna
design
target
hpv
mrna
encod
protein
oncogen
activ
inocul
either
periton
caviti
subcutan
tumor
site
daili
day
twice
day
treat
group
tumor
growth
smaller
express
hpv
protein
much
lower
sometim
almost
undetect
apoptosi
tumor
tissu
higher
compar
control
feasibl
use
sirna
hepat
g
viru
flaviviru
marmoset
examin
anim
inocul
intraven
sirnacation
liposom
target
site
untransl
region
viru
differ
hcv
also
flaviviru
two
nucleotid
sirna
treatment
protocol
marmoset
infect
liver
day
hepat
g
viru
plasma
anoth
infect
monkey
treat
monkey
show
delay
infect
control
initi
lower
plasma
viral
load
month
group
induc
ifn
would
suppress
viru
although
possibl
two
differ
routeson
local
induct
one
specif
induct
hiv
replic
studi
extens
vitro
use
rnai
therapeut
design
rnai
strategi
may
complex
much
known
challeng
treatment
acut
infect
mild
indistinguish
sever
infect
individu
may
know
acut
hiv
infect
therefor
rnai
therapi
would
like
focu
chronic
infect
acut
infect
viru
travel
mani
reservoir
cell
type
throughout
bodi
establish
persist
latent
infect
may
detect
sever
year
deliveri
rnai
therapeut
agent
would
need
reach
site
also
makeup
quasispeci
carri
infect
individu
constantli
chang
aris
small
sequenc
variat
could
affect
efficaci
design
nucleic
acidbas
therapi
viru
replic
quickli
easili
select
escap
resist
mutant
respons
antiretrovir
therapi
complic
mani
subtyp
found
global
distinct
sequenc
variat
viru
recombin
easili
among
subtyp
form
circul
recombin
form
final
anim
model
complet
encompass
featur
make
vivo
evalu
new
therapeut
agent
rnai
difficult
sever
rnai
therapeut
studi
target
hostcel
receptor
viru
earli
studi
evalu
use
sirna
cellular
gene
well
viral
gene
encod
gag
protein
although
data
show
approach
promis
sirna
transfect
hour
prior
hiv
infect
author
suggest
might
better
target
subsequ
studi
success
target
express
protein
seem
dispens
human
hiv
tend
infect
cell
receptor
earli
hiv
infect
downregul
host
gene
shown
cell
line
carri
sirna
shrna
ribozym
deliv
lentiviru
vector
lead
reduct
hiv
viral
load
one
studi
incorpor
second
shrna
gene
vector
show
biphas
shrnavector
could
also
work
success
peripher
blood
mononuclear
cell
interest
report
abil
tat
protein
made
hivinfect
cell
abl
circumv
rnai
suppress
dicer
activ
suggest
shrna
might
effect
hivinfect
cell
would
need
process
dicer
short
precut
sirna
deliv
cell
would
bypass
block
vector
construct
use
phase
hiv
rnai
trial
lentiviru
capabl
infect
cell
activ
divid
sirna
target
tatrev
region
hiv
genom
sequenc
construct
allow
activ
bind
splice
unsplic
mrna
found
infect
cell
may
silenc
hiv
gene
two
differ
replic
stage
two
studi
examin
potenti
rnai
suppress
infect
differ
subtyp
shrna
conserv
region
subtyp
c
gag
subtyp
b
gag
rev
vif
test
infect
clinic
isol
differ
geograph
origin
phenotyp
characterist
silenc
activ
subtyp
c
shrna
gag
vari
depend
clinic
isol
activ
shrna
subtyp
b
vif
success
abl
inhibit
infect
subtyp
b
strain
china
unit
state
well
recombin
bc
strain
sequenc
analysi
indic
target
mrna
highli
conserv
within
bind
region
shrna
could
toler
variat
end
emphas
import
inform
design
sirna
shrna
report
escap
mutat
hiv
treat
rnai
reinforc
data
observ
rnai
viru
infect
appear
escap
mutant
surpris
especi
knowledg
gain
develop
use
antiretrovir
drug
studi
indic
replic
viru
develop
mutat
shrna
resist
develop
week
vitro
type
mutat
vari
mutat
point
mutat
escap
mechan
includ
delet
bp
remov
bind
site
target
sirna
acquisit
mutat
sequenti
also
observ
develop
mutat
outsid
sirna
bind
site
target
viru
develop
differ
fold
secondari
structur
caus
target
site
inaccess
sirna
thorough
studi
site
target
alter
systemat
evalu
bind
sirna
data
similar
report
subtyp
bind
indic
vulner
base
caus
loss
sirna
bind
efficaci
center
target
sequenc
flank
center
region
toler
shown
extrem
end
like
therapi
use
rnai
tailor
target
viru
current
rnai
design
seem
less
complic
virus
caus
acut
infect
rsv
infect
model
show
specif
tissu
target
sirna
treatment
nonvirem
infect
suggest
primari
tissu
site
access
mucos
origin
treat
sirna
efficaci
suppress
acut
infect
deliv
simpl
transfect
physiolog
medium
rnai
may
effect
microbicid
phase
ii
trial
test
rnai
rsv
infect
announc
june
reinforc
potenti
sirna
inhal
therapeut
agent
influenza
sarscov
flaviviru
model
demonstr
possibl
benefit
use
rnai
therapi
follow
viral
exposur
deliveri
agent
optim
show
design
rnai
sequenc
target
region
highli
conserv
sequenc
might
also
increas
potenti
use
relat
virus
wider
geograph
distribut
rnai
therapi
model
chronic
infect
address
issu
involv
stabil
deliveri
agent
rnai
initi
site
viru
enter
host
may
differ
locat
chronic
infect
establish
import
identifi
nontox
compoundssolut
could
select
deliv
agent
rnai
tissu
difficult
reach
like
heart
muscl
without
signific
toxic
studi
suggest
rnai
could
use
interven
chronic
diseas
either
sirna
shrna
deliv
nonrepl
viral
vector
prolong
efficaci
rnai
suppress
process
associ
chronic
diseas
oncogenesi
inflamm
impli
design
rnai
therapi
chronic
hiv
infect
simpl
feasibl
anim
model
avail
presenc
escap
mutat
sequenc
variat
vitro
hiv
infect
indic
problem
face
convent
antiretrovir
therapi
also
exist
rnai
therapi
use
combin
therapi
rnai
current
antiretrovir
strategi
may
viabl
strategi
circumv
problem
longterm
express
agent
rnai
multipl
reservoir
cell
still
challeng
attract
rnai
hiv
therapeut
natur
biolog
mechan
may
much
less
associ
toxic
face
lifelong
treatment
also
may
less
expens
current
therapi
great
interest
see
clinic
trial
use
rnai
fare
potenti
conflict
interest
relev
articl
report
paper
particular
interest
publish
recent
highlight
import
major
import
